Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The objective of this post hoc analysis was to examine the incidence of 3-point MACE, including nonfatal myocardial infarction (MI), nonfatal ischemic stroke, and CV death, across different categories of weight loss achieved after 13 months of semaglutide treatment in the SUSTAIN-6 trial, as well as assess the association between weight loss categories and the incidence of MACE outcomes during the subsequent follow-up period (weeks 56104)
Beyond genetics, clinical monitoring remains essential
doi:10.1016/S2213-8587(19)30344-3
The O/PEs were stored for a maximum of 1 week in 1% PFA at 4 C
US$ 21.15
US$ 20.31
US$ 29.71
US$ 21.81
US$ 26.46
